Cochrane Review Group

Eyes and Vision

171 systematic reviews in Eyes and Vision ask 2,112 questions. 27.8% have no studies to answer them, 21.1% rest on very low certainty evidence and 20.2% reach moderate or high certainty.

Reviews

171

Questions

2,112

current versions

No studies

27.8%

Moderate or high

20.2%

No studies 587 · 27.8%Ungraded 95 · 4.5%Very low 446 · 21.1%Low 557 · 26.4%Moderate 361 · 17.1%High 66 · 3.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Eyes and Vision

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
LipiFlow vs basic warm compresses Mean change from baseline in symptom scores at 1 to 4 weeks (lower is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane	no estimate extracted	NR	Very low
LipiFlow vs thermostatic devices Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane	no estimate extracted	4 studies · 445 participants	Very low
LipiFlow vs basic warm compresses Mean change from baseline in meibomian gland expression scores at 1 to 4 weeks (higher is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane	SMD 1.31	2 studies · 76 participants	Very low
LipiFlow vs basic warm compresses Mean change from baseline in meibum quality scores at 1 to 4 weeks (higher is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane	no estimate extracted	1 study · 46 participants	Very low
LipiFlow vs thermostatic devices Mean change from baseline in symptom scores at 1 to 4 weeks (lower is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane	no estimate extracted	NR	Very low
Face‐down positioning vs other positioning Proportion of eyes with retinal displacement at 6 months or later (RR < 1 favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane	RR 0.73 [0.54, 0.99]	1 study · 239 participants	Very low
Face‐down positioning vs other positioning Mean change in logMAR or Snellen visual acuity from baseline to 3 months or later (lower is favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane	no estimate extracted	1 study · 56 participants	Very low
Face‐down positioning vs other positioning Mean objective distortion score at 3 months or later (lower is favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane	MD 1.8	1 study · 219 participants	Very low
Face‐down positioning vs other positioning Quality of life assessments at 3 months or later (higher is favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane	no estimate extracted	1 study · 217 participants	Very low
Face‐down positioning vs other positioning Frequency of intervention‐related ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane	no estimate extracted	1 study · 262 participants	Very low
Face‐down positioning vs other positioning Frequency of intervention‐related non‐ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane	no estimate extracted	NR	No studies
Lutein with or without zeaxanthin vs placebo Adverse effects · people with AMD Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration (2023) · Cochrane	OR 1.06	NR	Very low

Reviews 171

Artificial intelligence for detecting keratoconus

Vandevenne, MMS, Favuzza, E, et al. · Cochrane Database of Systematic Reviews · 2023

Eyes and Vision

Thinnest evidence

Reviews 171

Artificial intelligence for detecting keratoconus

Pars plana vitrectomy with internal limiting membrane flap versus pars plana vitrectomy with conventional internal limiting membrane peeling for large macular hole

Topical ophthalmic anesthetics for corneal abrasions

Lens extraction versus laser peripheral iridotomy for acute primary angle closure

Surgical interventions for bilateral congenital cataract in children aged two years and under

Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension

Non‐steroidal anti‐inflammatory agents for treating cystoid macular edema following cataract surgery

Rituximab for thyroid‐associated ophthalmopathy

Amniotic membrane transplantation for acute ocular burns

Binocular versus standard occlusion or blurring treatment for unilateral amblyopia in children aged three to eight years

Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure

Immediate sequential bilateral surgery versus delayed sequential bilateral surgery for cataracts

Tocilizumab for giant cell arteritis

Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis

Early vitrectomy for exogenous endophthalmitis following surgery

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension

Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis

Antibiotic prophylaxis for corneal abrasion

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults

Topical corticosteroids for dry eye

Interventions for intermittent exotropia

Lens extraction for chronic angle‐closure glaucoma

Laser peripheral iridoplasty for chronic angle closure

Pneumatic retinopexy versus scleral buckle for repairing simple rhegmatogenous retinal detachments

Fornix‐based versus limbal‐based conjunctival trabeculectomy flaps for glaucoma